The May 2026 FDA approval of vepdegestrant (Veppanu®; Rigel Pharmaceuticals)*, previously known as ARV-471, marks a transformative advance in the treatment of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer. Vepdegestrant is the first-in-class, orally administered PROteolysis TArgeting Chimera (PROTAC) protein degrader to reach the clinic, offering a novel mechanism of action that overcomes endocrine resistance driven by ESR1 mutations—a dominant mechanism of therapeutic failure in the ER+/HER2− metastatic breast cancer population.[1]
In this article, we review vepdegestrant’s clinical trial efficacy, safety profile, mechanism of action, place in therapy, and the broader implications of PROTAC technology for the future of oncology.
A novel treatment approach
Breast cancer remains the most common cancer among women worldwide, and the majority of cases are ER-positive (ER+). Endocrine therapies targeting the estrogen receptor have long been the cornerstone of management for advanced or metastatic ER+/HER2− breast cancer. However, resistance inevitably develops, with mutations in the ESR1 (estrogen receptor 1) gene representing a key mechanism of acquired resistance. These mutations alter the estrogen receptor’s binding site, rendering standard therapies such as selective estrogen receptor modulators (SERMs), aromatase inhibitors, and even selective estrogen receptor degraders (SERDs) less effective.[2][3][4]
The need for therapies that can effectively target and overcome ESR1-mutant breast cancer is acute. Vepdegestrant, developed by Arvinas and Pfizer, addresses this therapeutic gap by leveraging the PROTAC platform—a technology that enables selective degradation of disease-driving proteins. In May 2026, vepdegestrant became the first FDA-approved PROTAC therapy, ushering in a new era of precision oncology.
Indication and Patient Selection
Vepdegestrant is indicated for the treatment of adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer that has progressed following at least one line of endocrine therapy. Critically, patients must test positive for an ESR1 mutation using an FDA-authorized diagnostic, such as the Guardant360 CDx, which was co-approved as a companion diagnostic.[5]
This indication fills a critical unmet need: ESR1 mutations are detected in approximately 40–50% of patients whose disease has progressed on endocrine therapy and a CDK4/6 inhibitor. These patients often face rapid clinical deterioration and limited treatment options.
Mechanism of Action: PROTACs vs. Traditional Therapies
Vepdegestrant is a heterobifunctional small molecule—classified as a PROTAC—engineered to degrade the estrogen receptor (ER). Unlike traditional endocrine therapies, which generally inhibit or block the ER, vepdegestrant harnesses the cell’s ubiquitin-proteasome system to eliminate the receptor entirely.
A PROTAC consists of two distinct ligand ends connected by a chemical linker: one end binds the target protein (ER), while the other recruits an E3 ubiquitin ligase. Upon binding, the PROTAC brings the ER and E3 ligase into proximity, initiating ubiquitination of the ER and its subsequent destruction via the proteasome. This event-driven, catalytic mechanism distinguishes PROTACs from merely inhibitory drugs—enabling the complete and repeated removal of the disease-driving protein, including those with resistance-conferring mutations.[2][3][4]
PROTACs vs. Antibody-Drug Conjugates
It is crucial to distinguish PROTACs from other targeted therapies, such as Antibody-Drug Conjugates (ADCs). Whereas PROTACs are small molecules that catalytically degrade intracellular proteins, ADCs are biologics composed of a monoclonal antibody linked to a cytotoxic payload, which is delivered to cell-surface antigens and internalized, releasing the toxin to kill the cell.
ADCs are administered as intravenous infusions, whereas vepdegestrant is administered orally—highlighting its convenience and potential to improve patient adherence.
Clinical Development: The VERITAC-2 Trial
The efficacy and safety of vepdegestrant were established in the pivotal Phase 3 VERITAC-2 trial (NCT05654623), a randomized, multicenter, open-label study. The trial enrolled 624 adults with ER+/HER2− advanced or metastatic breast cancer, with 270 harboring ESR1 mutations identified via ctDNA analysis. Eligible patients had progressed on one to two lines of endocrine therapy, including at least one regimen with a CDK4/6 inhibitor.
Patients were randomized 1:1 to receive vepdegestrant 200 mg orally once daily with food, or fulvestrant, a standard-of-care SERD administered intramuscularly. Stratification was performed based on ESR1 mutation status and the presence of visceral metastases. Treatment continued until disease progression or unacceptable toxicity.
Efficacy Results
The primary endpoint was progression-free survival (PFS) by blinded independent central review (BICR), evaluated both in the ESR1-mutant subgroup and the overall population. In patients with ESR1-mutant tumors, Veppanu demonstrated a statistically significant and clinically meaningful improvement in PFS:
* Median PFS: 5.0 months (vepdegestrant) vs. 2.1 months (fulvestrant)
* Hazard ratio: 0.57 (95% CI: 0.42–0.77; p=0.0001)
* Objective response rate (ORR): 19% (vepdegestrant) vs. 4% (fulvestrant)
At the time of analysis, overall survival (OS) data were immature, with 16% of events reported. Nevertheless, the substantial PFS benefit firmly establishes Veppanu as a new standard for ESR1-mutant, ER+/HER2− advanced breast cancer after progression on endocrine therapy.
Safety Profile
Vepdegestrant’s safety was comparable to fulvestrant, with most adverse events (AEs) being low grade (Grade 1–2). The most common AEs (≥10%) included decreased white blood cells, elevated liver enzymes (AST, ALT, alkaline phosphatase), musculoskeletal pain, fatigue, anemia, neutropenia, increased bilirubin, decreased appetite, prolonged QT interval, thrombocytopenia, and constipation. Importantly, the oral administration of Veppanu offers a significant quality-of-life advantage over intramuscular SERDs, reducing treatment burden for patients.
Dosing and Administration
The recommended dose of Veppanu is 200 mg orally once daily, taken consistently with food. This simple oral regimen contrasts favorably with fulvestrant and other injectable SERDs, potentially improving adherence and patient satisfaction.
Before initiation, patients must have documented ESR1 mutation status using an FDA-authorized test. The Guardant360 CDx is the approved companion diagnostic for this purpose, utilizing a minimally invasive blood-based ctDNA assay.
Place in Therapy and Unmet Needs
The approval of Veppanu addresses a longstanding unmet need in the management of endocrine-resistant, ESR1-mutant ER+/HER2− advanced breast cancer. Until now, options for patients progressing on endocrine therapy and CDK4/6 inhibitors were limited and often associated with poor outcomes. While chemotherapy and other systemic agents are available, they are frequently accompanied by greater toxicity and diminished quality of life.
By directly targeting and degrading the mutated estrogen receptor—the primary driver of resistance—Veppanu provides a rational, precision-medicine solution. Its oral administration and manageable safety profile further enhance its value proposition.
Broader Impact: PROTACs as a New Therapeutic Paradigm
Vepdegestrant’s approval is not only a milestone for breast cancer but also for the broader field of targeted protein degradation. PROTACs represent a fundamentally new therapeutic modality, capable of degrading previously ‘undruggable‘ targets. This approach opens possibilities for treating cancers and other diseases driven by pathogenic proteins that cannot be effectively inhibited by conventional small molecules or monoclonal antibodies.
Arvinas, the company responsible for vepdegestrant’s development, has an expanding clinical pipeline of PROTAC degraders targeting other oncogenic drivers, such as KRAS (ARV-806), BCL6 (ARV-393), and HPK1 (ARV-6723)—with early clinical data showing promise in solid tumors and hematologic malignancies. These efforts demonstrate the versatility and catalytic efficiency of the PROTAC platform.
Discussion: Mechanistic and Clinical Distinctions
The distinction between PROTACs and traditional inhibitors is more than semantic. By eliminating the target protein, PROTACs can overcome resistance mechanisms that arise from mutations in the protein’s active site or increased protein expression. This is especially relevant for ESR1 mutations, which often emerge under the selective pressure of endocrine therapy and confer ligand-independent ER activity.
Furthermore, PROTACs function catalytically: a single molecule can degrade multiple target proteins, amplifying their potency. This catalytic action, combined with the oral dosing of Veppanu, suggests a powerful new model for chronic cancer therapy.
Comparison with ADCs highlights further differences. ADCs deliver a cytotoxic payload directly to cancer cells via a monoclonal antibody, relying on cell surface protein expression for selectivity. PROTACs, by contrast, operate intracellularly, are smaller in size, and can target proteins regardless of cell surface expression.
Limitations and Future Directions
While vepdegestrant represents a major advance, there are ongoing challenges. Not all patients with ESR1 mutations respond, and resistance may eventually develop even to PROTAC-based therapies. Ongoing research is focused on understanding these resistance mechanisms, optimizing degrader selectivity and potency, and expanding the range of targetable proteins.
Additionally, the long-term safety profile of PROTACs, especially in combination with other agents, remains under investigation. Future studies will clarify the optimal sequencing and combination strategies for Veppanu and other degraders in the metastatic breast cancer treatment paradigm.
Conclusion
The approval of vepdegestrant represents a landmark in oncology, offering the first FDA-approved PROTAC-based therapy for a defined population of patients with advanced or metastatic, ER+/HER2−, ESR1-mutated breast cancer. Its approval validates the targeted protein degradation approach and provides a new precision-medicine option for patients with limited alternatives. With ongoing research and additional PROTACs in development, this technology promises to reshape the landscape of cancer therapeutics and beyond.
__
Note:* Vepdegestrant (Veppanu®) was developed by Arvinas in partnership with Pfizer. On May 1, 2026, the Food and Drug Administration approved the drug. In May 2026, Arvinas and Pfizer granted Rigel Pharmaceuticals exclusive global rights to develop, manufacture, and commercialize vepdegestrant (Veppanu®), the first FDA-approved PROTAC protein degrader. Rigel will lead the U.S. launch and commercialization, and can sublicense vepdegestrant internationally. Arvinas and Pfizer will receive a $70 million upfront payment, an additional $15 million for certain transition milestones, up to $320 million in future milestone payments, and tiered royalties on global sales, all shared equally. Rigel will also contribute up to $40 million toward ongoing development, while Arvinas and Pfizer remain responsible for current development activities and will receive a share of any international sublicensing revenue.
Clinical trials
A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer (VERITAC-2) – ClinicalTrials.gov ID NCT05654623
Highlights of Prescribing Information
Vepdegestrant (Veppanu®; Rigel Pharmaceuticals) [Prescribing Information]
References
[1] FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. U.S. Foof and Drug Administration (FDA). Online. Last accessed on May 20, 2026
[2] Campone M, De Laurentiis M, Jhaveri K, Hu X, Ladoire S, Patsouris A, Zamagni C, Cui J, Cazzaniga M, Cil T, Jerzak KJ, Fuentes C, Yoshinami T, Rodriguez-Lescure A, Sezer A, Fontana A, Guarneri V, Molckovsky A, Mouret-Reynier MA, Demirci U, Zhang Y, Valota O, Lu DR, Martignoni M, Parameswaran J, Zhi X, Hamilton EP; VERITAC-2 Study Group. Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer. N Engl J Med. 2025 Aug 7;393(6):556-568. doi: 10.1056/NEJMoa2505725. Epub 2025 May 31. PMID: 40454645.
[3] Gough SM, Flanagan JJ, Teh J, Andreoli M, Rousseau E, Pannone M, Bookbinder M, Willard R, Davenport K, Bortolon E, Cadelina G, Gordon D, Pizzano J, Macaluso J, Soto L, Corradi J, Digianantonio K, Drulyte I, Morgan A, Quinn C, Békés M, Ferraro C, Chen X, Wang G, Dong H, Wang J, Langley DR, Houston J, Gedrich R, Taylor IC. Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models. Clin Cancer Res. 2024 Aug 15;30(16):3549-3563. doi: 10.1158/1078-0432.CCR-23-3465. PMID: 38819400; PMCID: PMC11325148.
[4] Hamilton EP, Ma C, De Laurentiis M, Iwata H, Hurvitz SA, Wander SA, Danso M, Lu DR, Perkins Smith J, Liu Y, Tran L, Anderson S, Campone M. VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer. Future Oncol. 2024;20(32):2447-2455. doi: 10.1080/14796694.2024.2377530. Epub 2024 Jul 29. PMID: 39072356; PMCID: PMC11524203.
[5] Mukohara T. Vepdegestrant for the treatment of HR+/HER2- breast cancer. Expert Opin Pharmacother. 2025 May;26(7):791-799. doi: 10.1080/14656566.2025.2488456. Epub 2025 Apr 9. PMID: 40177927.
[5] Guardant360 CDx companion diagnostic information.[website]
Featured image courtesy: © 2016 – 2026 Fotolia/Adobe. Used with permission
DOI
*, previously known as ARV-471, marks a transformative advance in the treatment of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer. Vepdegestrant is the first-in-class, orally administered PROteolysis TArgeting Chimera (PROTAC) protein degrader to reach the clinic, offering a novel mechanism of action that overcomes endocrine resistance driven by ESR1 mutations—a dominant mechanism of therapeutic failure in the ER+/HER2− metastatic breast cancer population.){kind=link}